Print Page     Close Window     
20-F
MESOBLAST LTD filed this Form 20-F on 08/31/2018
Entire Document
 
meso-ex991_253.htm

 

Exhibit 99.1

Appendix 4E

Preliminary final report for the twelve months to 30 June 2018

 

Name of entity

MESOBLAST LIMITED

ABN 68 109 431 870

 

1.

Reporting period

 

Report for the financial year ended

30 June 2018

Previous corresponding period is the financial year ended

30 June 2017

 

2.

Results for announcement to the market

 

 

Up/down

% change

 

Amount reported for the year ended 30 June  2018

USD’000

Revenues from ordinary activities (item 2.1)

 

Up

618.9%

to

17,341

Loss from ordinary activities after tax attributable to members (item 2.2)

Down*

54.1%

to

35,290

 

 

 

 

 

Net loss for the period attributable to members (item 2.3)

Down*

54.1%

to

35,920

*decrease in loss

 

 

 

 

 

There are no dividends being proposed or declared for the period (item 2.4 and 2.5)

 

Commentary related to the above results

Please refer to ‘Item 5.A Operating results’ within the Form 20-F for the year ended 30 June 2018.

 

 

3.

Net tangible assets per security

 

 

30 June 2018

30 June 2017

Net tangible asset/(liability) backing

per ordinary security (in USD cents)

4.88 cents

10.11 cents

 

A large proportion of the company’s assets are intangible in nature, consisting of intellectual property and goodwill relating to the acquisition of Mesoblast, Inc and culture-expanded Mesenchymal Stem Cells technology. These assets and the associated provision for contingent consideration are excluded from the calculation of net tangible assets per security.  The deferred tax liability has also been excluded from the calculation to the extent it relates to future tax obligations as a result of the intellectual property assets deriving revenue at some point in the future. This deferred tax liability has arisen as a result of the intellectual property being acquired.

 

-1-



Copyright © 2015 Mesoblast Inc.